Physician profile
Jonathon E Thygeson
NPI 1790744704
$4,757.71
in general payments reported to CMS, 2019-2025
23 companies · $940 in 2025
The $940 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $802 · 2021: $856 · 2022: $493 · 2023: $659 · 2024: $660 · 2025: $940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,258.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $1,068.37 | 2019-2025 | Dyanavel Xr, Quillivant, Onyda Xr |
| Glaxosmithkline, LLC. | $629.03 | 2019-2025 | Bexsero, Penmenvy |
| Kaleo, INC. | $535.54 | 2019-2024 | Auvi-Q |
| Pfizer INC. | $318.95 | 2020-2025 | |
| Ironshore Pharmaceuticals INC. | $270.54 | 2019-2021 | |
| Adlon Therapeutics L.P. | $262.86 | 2020-2021 | |
| Seqirus USA INC | $220.33 | 2022-2025 | Flucelvax Quadrivalent, Flucelvax |
| Sanofi Pasteur INC. | $209.08 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $179.38 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $153.62 | 2020-2025 | Vaxelis, Gardasil 9, Vaxneuvance |
| Corium, LLC | $152.49 | 2022-2024 | Azstarys |
| Lnhc, INC | $130.00 | 2025 | Zelsuvmi |
| Sobi, INC | $119.36 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $107.23 | 2022-2024 | Flumist Quadrivalent |
| Cranial Technologies, INC | $93.52 | 2020-2025 | Doc Band |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $87.81 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $52.85 | 2025 | Neffy |
| Verrica Pharmaceuticals INC. | $41.87 | 2025 | Ycanth |
| Biomarin Pharmaceutical INC. | $35.25 | 2025 | Voxzogo 1.2mg |
| Biomerieux INC | $24.70 | 2025 | Biofire Spotfire Control Station |
| Alk-Abello, INC | $23.88 | 2025 | Neffy, Grastek, Odactra |
| Kowa Pharmaceuticals America, INC. | $21.96 | 2025 | Zoryve |
| Cognoa, INC. | $19.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathon Thygeson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.